T he use of in vivo imaging techniques for assessing choline metabolism to detect cancer is supported by studies showing increased choline kinase and transporter gene expression, transmembrane choline transport, and tissue choline metabolite concentration in a number of malignancies [1, 2] . Early clinical studies employing techniques for in vivo imaging of choline metabolism looked promising, with early PET studies demonstrating increased choline tracer uptake in a variety of tumors, and independently, studies employing proton magnetic resonance spectroscopy (1H-MRS) demonstrating increased tissue levels of choline metabolites in several malignancies [2] [3] [4] [5] . However, the use of these two very different in vivo methods to study choline metabolism have raised questions as to how their measurements interrelate; and there have been instances where choline tracer uptake on PET fails to correlate well with the tissue measurements of choline provided by 1H-MRS [6] .
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To address these questions, Rommel et al., in their study titled "Rodent Rhabdomyosarcoma: Comparison Between Total Choline Concentration at 1H-MRS and [
18 F]-fluoromethylcholine (FCH) Uptake at PET Using Accurate Methods for Collecting Data", employed methods for achieving highly accurate spatial correspondence between small-animal PET and MRI to study the relationship between FCH uptake and spectroscopic measurement of tissue choline metabolites in a rhabdomyosarcoma animal model. Their study did not confirm a quantitative relationship between tumor FCH uptake and measures of choline concentration obtained with 1H-MRS in their experimental model. The authors offered several biological hypotheses to explain the lack of correlation between FCH uptake and choline metabolite concentration: one involving the presence of a negative feed-back mechanism of elevated levels of intracellular choline compounds on FCH uptake; another involving the rapid transport and incorporation of choline into membrane phosphatidylcholine (which is not detectable by 1H-MRS) to explain increases in FCH uptake without corresponding increases in total choline metabolite concentration on 1H-MRS.
In addition to these biological hypotheses, the limited ability of in vivo 1H-MRS to discriminate specific choline metabolites may also be worth considering as a potential explanation for their observations. Specifically, the "choline peak" at 3.2 ppm that is often used for in vivo 1H-MRS studies is known to actually reflect a number of important choline metabolites [7] . Ex vivo and in vitro NMR can readily differentiate several of these metabolites bearing the choline moiety. They include free choline, phosphocholine (PC; at 3.23 ppm), and glycerophosphocholine (GPC; at 3.24 ppm) [8, 9] . However, due to their spectral proximity it has proven difficult to resolve these compounds in vivo [2] . PC is a predominant biosynthetic product whose concentrations in malignancy can increase as a result of choline kinase upregulation [1] . GPC, on the other hand, is primarily a product of phospholipase activation [10, 11] . In the study by Rommel et al., the inability to separate the spectral contributions of these biochemically distinct compounds should raise the question of whether FCH uptake is actually being compared to the net result of several anabolic and catabolic processes in the CDP-choline pathway. Such a situation could potentially explain the lack of correlation observed between total choline concentration and FCH uptake.
Work by DeGrado et al. has suggested FCH to be a marker of biosynthetic PC metabolism with specificity for the transmembrane choline transporter and choline kinase [12, 13] . Consequently, the tissue concentration of PC, rather than total choline, may correlate best with FCH uptake. The relationship between PC and GPC metabolism under some tumor conditions has been studied. For example, activation of phospholipase can decrease PC and increase GPC levels in breast and prostate cancer cells, potentially leading to a less aggressive phenotype [11, 14] . Exposure to chemotherapeutic agents can also decrease tissue levels of PC while increasing the levels of GPC [15, 16] . These results suggest the possibility of assessing tumor therapeutic response through specific measurement of PC or GPC metabolism. We look forward to future studies comparing FCH PET to other methods for measuring PC metabolism in vivo.
